Mouse models of autoimmune diseases - autoimmune myocarditis

Current Pharmaceutical Design

Volumn 21, Issue 18, 2015, Pages 2498-2512

  Müller, Anna Maria ^a   Fischer, Andrea ^a   Katus, Hugo A ^a   Kaya, Ziya ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Animal models; Autoimmunity; Coxsackievirus B3; DCM; Myocarditis; Myosin; Troponin I

Indexed keywords

CARDIAC MYOSIN; CARDIAC TROPONIN 1; TROPONIN I; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL MODEL; ARTICLE; AUTOIMMUNE MYOCARDITIS; CLINICAL FEATURE; DENDRITIC CELL; EXPERIMENTAL AUTOIMMUNE DISEASE; EXPERIMENTAL CARDIOVASCULAR DISEASE; GENETIC SIMILARITY; HEART MUSCLE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; MOUSE; MOUSE MODEL; MURINE MODEL; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS MYOCARDITIS; ANIMAL; AUTOIMMUNE DISEASES; DISEASE MODEL; METABOLISM; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MICE; MYOCARDITIS;

EID: 84929629188     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150316123711     Document Type: Article

References (141)

1. [1] Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014; 129(3): e28-e292.
2. [2] WHO. Causes of death in 2008: World Health Organization; 2008 [cited 2014 14-09-22]. Available from: http://www.who.int/gho/mortality_burden_disease/causes_death_2008/en/.
3. [3] Richardson P, McKenna W, Bristow M, et al. Report of the 1995 world health organization/international society and federation of cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996; 93(5): 841-2.
4. [4] Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34(33): 2636-48
5. [5] Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32(21): 2616-25.
6. [6] Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012; 21(4): 245-74.
7. [7] Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012; 59(9): 779-92.
8. [8] Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118(6): 639-48.
9. [9] Helin M, Savola J, Lapinleimu K. Cardiac manifestations during a Coxsackie B5 epidemic. Br Med J 1968; 3(5610): 97-9.
10. [10] Grist NR, Bell EJ. Coxsackie viruses and the heart. Am Heart J 1969; 77(3): 295-300.
11. [11] Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an american heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation 2006; 113(14): 1807-16.
12. [12] Amabile N, Fraisse A, Bouvenot J, Chetaille P, Ovaert C. Outcome of acute fulminant myocarditis in children. Heart 2006; 92(9): 1269-73.
13. [13] Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart 2006; 92(3): 316-20.
14. [14] Cocker MS, Abdel-Aty H, Strohm O, Friedrich MG. Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study. Heart 2009; 95(23): 1925-30.
15. [15] Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. N Engl J Med 1995; 333(5): 269-75.
16. [16] Grimm W, Glaveris C, Hoffmann J, et al. Arrhythmia risk stratification in idiopathic dilated cardiomyopathy based on echocardiography and 12-lead, signal-averaged, and 24-hour holter electrocardiography. Am Heart J 2000; 140(1): 43-51.
17. [17] Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Cardiac Fail 2010; 16(6): e1-194.
18. [18] Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the american college of cardiology foundation/american heart association task force on practice guidelines developed in collaboration with the international society for heart and lung transplantation. J Am Coll Cardiol 2009; 53(15): e1-e90.
19. [19] Liu PP, Schultheiss HP. Myocarditis. In: Braunwald E, ed. Heart Disease. 8th ed. Philadelphia: W B Saunders Co; 2008; pp. 1775-92.
20. [20] Freimuth P, Philipson L, Carson SD. The coxsackievirus and adenovirus receptor. Curr Top Microbiol Immunol 2008; 323: 67-87.
21. [21] Li Z, Liu Y, Shi B, Wu X, Zhu J, Wang Z. An experimental study on anterior cruciate ligament reconstruction with remnants and remaining bundle preservation. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi = Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2009; 23(3): 282-6.
22. [22] Shi Y, Chen C, Lisewski U, et al. Cardiac deletion of the Coxsackievirus-adenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo. J Am Coll Cardiol 2009; 53(14): 1219-26.
23. [23] Noutsias M, Fechner H, de Jonge H, et al. Human coxsackieadenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections. Circulation 2001; 104(3): 275-80.
24. [24] Ambardekar AV, Lowery CM, Allen LA, et al. Effect of left ventricular assist device placement on preexisting implantable cardioverter-defibrillator leads. J Card Fail 2010; 16(4): 327-31.
25. [25] Ambardekar AV, Allen LA, Lindenfeld J, et al. Implantable cardioverter-defibrillator shocks in patients with a left ventricular assist device. J Heart Lung Transplant 2010; 29(7): 771-6.
26. [26] Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42(3): 466-72.
27. [27] Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 1999; 99(8): 1091-100.
28. [28] Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001; 104(9): 1076-82.
29. [29] Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the european society of intensive care medicine (ESICM). Eur Heart J 2008; 29(19): 2388-442.
30. [30] Schiff GM, Sherwood JR. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis 2000; 181(1): 20-6.
31. [31] Pauksen K, Ilback NG, Friman G, Fohlman J. Therapy of coxsackie virus B3-induced myocarditis with WIN 54954 in different formulations. Scand J Infect Dis Suppl 1993; 88: 125-30.
32. [32] Pinkert S, Westermann D, Wang X, et al. Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor. Circulation 2009; 120(23): 2358-66.
33. [33] Schultheiss HP, Kuehl, U. Cardiovascular viral infections. In: Lennette EH, ed. Lennette's Laboratory Diagnosis of Viral Infections. 4th ed. New York: Informa Healthcare USA Inc; 2010; pp. 304-18.
34. [34] Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Ann Rev Immunol 2005; 23: 275-306.
35. [35] Kuhl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107(22): 2793-8.
36. [36] Krueger GR, Ablashi DV. Human herpesvirus-6: a short review of its biological behavior. Intervirology 2003; 46(5): 257-69.
37. [37] Neumann DA, Burek CL, Baughman KL, Rose NR, Herskowitz A. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol 1990; 16(6): 839-46.
38. [38] Rose NR. Myocarditis: infection versus autoimmunity. J Clin Immunol 2009; 29(6): 730-7.
39. [39] Lauer B, Schannwell M, Kuhl U, Strauer BE, Schultheiss HP. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000; 35(1): 11-8.
40. [40] Wehlou C, Delanghe JR. Detection of antibodies in cardiac autoimmunity. Clin Chim Acta 2009; 408(1-2): 114-22.
41. [41] Kallwellis-Opara A, Dorner A, Poller WC, et al. Autoimmunological features in inflammatory cardiomyopathy. Clin Res 2007; 96(7): 469-80.
42. [42] Limas CJ, Goldenberg IF, Limas C. Autoantibodies against betaadrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res 1989; 64(1): 97-103.
43. [43] Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993; 91(5): 1964-8.
44. [44] Goser S, Andrassy M, Buss SJ, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 2006; 114(16): 1693-702.
45. [45] Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003; 107(6): 857-63.
46. [46] Stanton C, Mookadam F, Cha S, et al. Greater symptom duration predicts response to immunomodulatory therapy in dilated cardiomyopathy. Int J Cardiol 2008; 128(1): 38-41.
47. [47] Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104(1): 39-45.
48. [48] Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89(1): 252-7.
49. [49] Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann NY Acad Sci 2005; 1051: 743-78.
50. [50] Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res 2012; 110(1): 145-58.
51. [51] Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103(2): 220-5.
52. [52] English RF, Janosky JE, Ettedgui JA, Webber SA. Outcomes for children with acute myocarditis. Cardiol Young 2004; 14(5): 488-93.
53. [53] Wallukat G, Reinke P, Dorffel WV, et al. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 1996; 54(2): 191-5.
54. [54] Dorffel WV, Wallukat G, Baumann G, Felix SB. Immunoadsorption in dilated cardiomyopathy. Ther Apher 2000; 4(3): 235-8.
55. [55] Felix SB, Staudt A, Dorffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000; 35(6): 1590-8.
56. [56] Fields BNDMK, Robert MC, Joseph LM, Bernard R, Robert ES. Fields Virology. New York: Raven Press 1985.
57. [57] Libby K. Coxsackie B virus pathogen card 2000.
58. [58] Huber SA. Autoimmunity in myocarditis: relevance of animal models. Clin Immunol Immunopathol 1997; 83(2): 93-102.
59. [59] Huber SA. Animal models: Immunological aspects. London: Arnold 1993.
60. [60] Huber SA, Haisch C, Lodge PA. Functional diversity in vascular endothelial cells: role in coxsackievirus tropism. J Virol 1990; 64(9): 4516-22.
61. [61] Wilson FM, Miranda QR, Chason JL, Lerner AM. Residual pathologic changes following murine coxsackie A and B myocarditis. Am J Pathol 1969; 55(2): 253-65.
62. [62] Herzum M, Ruppert V, Kuytz B, Jomaa H, Nakamura I, Maisch B. Coxsackievirus B3 infection leads to cell death of cardiac myocytes. J Mol Cell Cardiol 1994; 26(7): 907-13.
63. [63] McManus BM, Chow LH, Wilson JE, et al. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol 1993; 68(2): 159-69.
64. [64] Hufnagel G, Chapman N, Tracy S. A non-cardiovirulent strain of coxsackievirus B3 causes myocarditis in mice with severe combined immunodeficiency syndrome. Eur Heart J 1995; 16 (Suppl O): 18-9.
65. [65] Arola A, Kalimo H, Ruuskanen O, Hyypia T. Experimental myocarditis induced by two different coxsackievirus B3 variants: aspects of pathogenesis and comparison of diagnostic methods. J Med Virol 1995; 47(3): 251-9.
66. [66] Woodruff JF, Woodruff JJ. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J Immunol 1974; 113(6): 1726-34.
67. [67] Beisel KW, Wolfgram LJ, Herskowitz A, Rose NR. Differences in severity of Coxsackievirus B3-induced myocarditis among H-2 congenic mouse strains. New York: E. Skamene 1985.
68. [68] Wolfgram LJ, Beisel KW, Herskowitz A, Rose NR. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J Immunol 1986; 136(5): 1846-52.
69. [69] Wolfgram LJ, Beisel KW, Rose NR. Heart-specific autoantibodies following murine coxsackievirus B3 myocarditis. J Exp Med 1985; 161(5): 1112-21.
70. [70] Herskowitz A, Wolfgram LJ, Rose NR, Beisel KW. The pathology of Coxsackievirus murine myocarditis: a quantitative study in multiple genetically defined inbred strains. Hum Pathol 1985; 16: 671.
71. [71] Woodruff JF, Kilbourne ED. The influence of quantitated postweaning undernutrition on coxsackievirus B3 infection of adult mice. I. Viral persistence and increased severity of lesions. J Infect Dis 1970; 121(2): 137-63.
72. [72] Huber SA, Job LP. Cellular immune mechanisms in Coxsackievirus group B, type 3 induced myocarditis in Balb/C mice. Adv Exp Med Biol 1983; 161: 491-508.
73. [73] Brinton MA, Blank KJ, Nathanson N. Host genes that influence susceptibility to viral disease. Nokins AL, ed. New York: Springer-Verlag 1984.
74. [74] Rose NR. Learning from myocarditis: mimicry, chaos and black holes. F1000prime Rep 2014; 6: 25.
75. [75] Aly M, Wiltshire S, Chahrour G, Osti JC, Vidal SM. Complex genetic control of host susceptibility to coxsackievirus B3-induced myocarditis. Genes Immun 2007; 8(3): 193-204.
76. [76] Fairweather D, Rose NR. Inflammatory heart disease: a role for cytokines. Lupus 2005; 14(9): 646-51.
77. [77] Fairweather D, Frisancho-Kiss S, Yusung SA, et al. Interferongamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol 2004; 165(6): 1883-94.
78. [78] Afanasyeva M, Georgakopoulos D, Fairweather D, Caturegli P, Kass DA, Rose NR. Novel model of constrictive pericarditis associated with autoimmune heart disease in interferon-gammaknockout mice. Circulation 2004; 110(18): 2910-7.
79. [79] Afanasyeva M, Georgakopoulos D, Belardi DF, et al. Impaired upregulation of CD25 on CD4+ T cells in IFN-gamma knockout mice is associated with progression of myocarditis to heart failure. Proc Natl Acad Sci USA 2005; 102(1): 180-5.
80. [80] Fairweather D, Frisancho-Kiss S, Gatewood S, et al. Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection. Autoimmunity 2004; 37(2): 131-45.
81. [81] Fairweather D, Yusung S, Frisancho S, et al. IL-12 receptor beta 1 and Toll-like receptor 4 increase IL-1 beta-and IL-18-associated myocarditis and coxsackievirus replication. J Immunol 2003; 170(9): 4731-7.
82. [82] Fairweather D, Frisancho-Kiss S, Yusung SA, et al. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFNgamma and macrophage and neutrophil populations in the heart. J Immunol 2005; 174(1): 261-9.
83. [83] Fairweather D, Rose NR. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 2007; 41(1): 118-22.
84. [84] Rose NR, Wolfgram LJ, Herskowitz A, Beisel KW. Postinfectious autoimmunity: two distinct phases of coxsackievirus B3-induced myocarditis. Ann N Y Acad Sci 1986; 475: 146-56.
85. [85] Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. From infection to autoimmunity. J Autoimmun 2001; 16(3): 175-86.
86. [86] Neu N, Beisel KW, Traystman MD, Rose NR, Craig SW. Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis. J Immunol 1987; 138(8): 2488-92.
87. [87] Cunningham MW. T cell mimicry in inflammatory heart disease. Mol Immunol 2004; 40(14-15): 1121-7.
88. [88] Gauntt CJ, Trousdale MD, LaBadie DR, Paque RE, Nealon T. Properties of coxsackievirus B3 variants which are amyocarditic or myocarditic for mice. J Med Virol 1979; 3(3): 207-20.
89. [89] Horwitz MS, La Cava A, Fine C, Rodriguez E, Ilic A, Sarvetnick N. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med 2000; 6(6): 693-7.
90. [90] Rose NR, Beisel KW, Herskowitz A, et al. Cardiac myosin and autoimmune myocarditis. Ciba Found Symp 1987; 129: 3-24.
91. [91] Neu N, Craig SW, Rose NR, Alvarez F, Beisel KW. Coxsackievirus induced myocarditis in mice: cardiac myosin autoantibodies do not cross-react with the virus. Clin Exp Immunol 1987; 69(3): 566-74.
92. [92] Beck MA, Levander OA, Handy J. Selenium deficiency and viral infection. J Nutr 2003; 133(5 Suppl 1): 1463S-7S.
93. [93] Beck MA, Kolbeck PC, Rohr LH, Shi Q, Morris VC, Levander OA. Benign human enterovirus becomes virulent in seleniumdeficient mice. J Med Virol 1994; 43(2): 166-70.
94. [94] Beck MA, Shi Q, Morris VC, Levander OA. Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nat Med 1995; 1(5): 433-6.
95. [95] Matsumori A, Kawai C. An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. Circulation 1982; 65(6): 1230-5.
96. [96] Cerutis DR, Bruner RH, Thomas DC, Giron DJ. Tropism and histopathology of the D, B, K, and MM variants of encephalomyocarditis virus. J Med Virol 1989; 29(1): 63-9.
97. [97] Maisch B, Berg PA, Kochsiek K. Autoantibodies and serum inhibition factors (sif) in patients with myocarditis. Klin Wochenschr 1980; 58(5): 219-25.
98. [98] Maisch B, Trostel-Soeder R, Stechemesser E, Berg PA, Kochsiek K. Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin Exp Immunol 1982; 48(3): 533-45.
99. [99] Alvarez FL, Neu N, Rose NR, Craig SW, Beisel KW. Heartspecific autoantibodies induced by Coxsackievirus B3: identification of heart autoantigens. Clin Immunol Immunopathol 1987; 43(1): 129-39.
100. [100] Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 1987; 139(11): 3630-6.
101. [101] Mercadier JJ, Bouveret P, Gorza L, et al. Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circ Res 1983; 53(1): 52-62.
102. [102] Caforio AL, Grazzini M, Mann JM, et al. Identification of alphaand beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85(5): 1734-42.
103. [103] Lauer B, Padberg K, Schultheiss HP, Strauer BE. Autoantibodies against human ventricular myosin in sera of patients with acute and chronic myocarditis. J Am Coll Cardiol 1994; 23(1): 146-53.
104. [104] Neumann DA, Rose NR, Ansari AA, Herskowitz A. Induction of multiple heart autoantibodies in mice with coxsackievirus B3-and cardiac myosin-induced autoimmune myocarditis. J Immunol 1994; 152(1): 343-50.
105. [105] Warraich RS, Noutsias M, Kazak I, et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J 2002; 143(6): 1076-84.
106. [106] Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006; 177(11): 8234-40.
107. [107] Freedman NJ, Lefkowitz RJ. Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Investig 2004; 113(10): 1379-82.
108. [108] Saito S, Hiroi Y, Zou Y, et al. Beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem 2000; 275(44): 34528-33.
109. [109] Lv H, Havari E, Pinto S, et al. Impaired thymic tolerance to alphamyosin directs autoimmunity to the heart in mice and humans. J Clin Investig 2011; 121(4): 1561-73.
110. [110] Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009; 9(12): 833-44.
111. [111] Khaw BA, Narula J, Sharaf AR, Nicol PD, Southern JF, Carles M. SR-Ca2+ ATPase as an autoimmunogen in experimental myocarditis. Eur Heart J 1995; 16 (Suppl O): 92-6.
112. [112] Schulze K, Schultheiss HP. The role of the ADP/ATP carrier in the pathogenesis of viral heart disease. Eur Heart J 1995; 16 (Suppl O): 64-7.
113. [113] Myers JM, Fairweather D, Huber SA, Cunningham MW. Autoimmune myocarditis, valvulitis, and cardiomyopathy. Current Protoc Immunol 2013; Chapter 15: Unit 15. 4. 1-51.
114. [114] Leuschner F, Katus HA, Kaya Z. Autoimmune myocarditis: past, present and future. J Autoimmun 2009; 33(3-4): 282-9.
115. [115] Donermeyer DL, Beisel KW, Allen PM, Smith SC. Myocarditisinducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. J Exp Med 1995; 182(5): 1291-300.
116. [116] Pummerer CL, Luze K, Grassl G, et al. Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. J Clin Investig 1996; 97(9): 2057-62.
117. [117] Leuschner F, Li J, Goser S, et al. Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction. Eur Heart J 2008; 29(16): 1949-55.
118. [118] Liao L, Sindhwani R, Leinwand L, Diamond B, Factor S. Cardiac alpha-myosin heavy chains differ in their induction of myocarditis. Identification of pathogenic epitopes. J Clin Investig 1993; 92(6): 2877-82.
119. [119] Daniels MD, Hyland KV, Wang K, Engman DM. Recombinant cardiac myosin fragment induces experimental autoimmune myocarditis via activation of Th1 and Th17 immunity. Autoimmunity 2008; 41(6): 490-9.
120. [120] Goehringer C, Rutschow D, Bauer R, et al. Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc Res 2009; 82(3): 404-10.
121. [121] Gonnella PA, Del Nido PJ, McGowan FX. Oral tolerization with cardiac myosin peptide (614-629) ameliorates experimental autoimmune myocarditis: role of STAT 6 genes in BALB/CJ mice. J Clin Immunol 2009; 29(4): 434-43.
122. [122] Kaya Z, Goser S, Buss SJ, et al. Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation 2008; 118(20): 2063-72.
123. [123] Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Investig 2005; 115(3): 518-26.
124. [124] Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108(7): 833-8.
125. [125] La Vecchia L, Mezzena G, Zanolla L, et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000; 19(7): 644-52.
126. [126] Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291(5502): 319-22.
127. [127] Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9(12): 1477-83.
128. [128] Eriksson S, Hellman J, Pettersson K. Autoantibodies against cardiac troponins. N Engl J Med 2005; 352(1): 98-100.
129. [129] Randhawa HS, Singh J, Lemaux PG, Gill KS. Mapping barley Ds insertions using wheat deletion lines reveals high insertion frequencies in gene-rich regions with high to moderate recombination rates. Genome 2009; 52(6): 566-75.
130. [130] Roussel M, Garnier S, Lemoine S, et al. Influence of a walking program on the metabolic risk profile of obese postmenopausal women. Menopause 2009; 16(3): 566-75.
131. [131] Thohan V, Stetson SJ, Nagueh SF, et al. Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey-Noon left ventricular assist device: a comparative analysis with pulsatile-type devices. J Heart Lung Transplant 2005; 24(5): 566-75.
132. [132] Zhou S, Breitenbach JM, Borysko KZ, et al. Synthesis and antiviral activity of (Z)-and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene] methylpurines and-pyrimidines: second-generation methylenecyclopropane analogues of nucleosides. J Med Chem 2004; 47(3): 566-75.
133. [133] Swanson DL, Olmstead KL. Evidence for a proximate influence of winter temperature on metabolism in passerine birds. Physiol Biochem Zool 1999; 72(5): 566-75.
134. [134] Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007; 73(3): 453-62.
135. [135] Muller OJ, Leuchs B, Pleger ST, et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adenoassociated viral vectors. Cardiovasc Res 2006; 70(1): 70-8.
136. [136] Grabie N, Delfs MW, Westrich JR, et al. IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis. J Clin Investig 2003; 111(5): 671-80.
137. [137] Nindl V, Maier R, Ratering D, et al. Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy. Eur J Immunol 2012; 42(9): 2311-21.
138. [138] Taylor JA, Havari E, McInerney MF, Bronson R, Wucherpfennig KW, Lipes MA. A spontaneous model for autoimmune myocarditis using the human MHC molecule HLA-DQ8. J Immunol 2004; 172(4): 2651-8.
139. [139] Yue-Chun L, Teng Z, Na-Dan Z, et al. Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. PloS one 2012; 7(6): e39394.
140. [140] Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cellmediated disease. J Immunol 1991; 147(7): 2141-7.
141. [141] Liao L, Sindhwani R, Rojkind M, Factor S, Leinwand L, Diamond B. Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med 1995; 181(3): 1123-31.